Company* |
Funding |
Amount |
Type# | Details (Date) |
Advanced |
National Institute of Neurological Disorders and Stroke |
ND |
Phase I SBIR grant |
Funds will support preclinical testing of the small molecule ALS-886 to reduce brain swelling leading to tissue damage following a stroke (2/7) |
Advanced |
Australian government |
A$1.4 ($1) |
Commercial Ready grant |
The funding will be provided over three years to match company funding and be used to support development (3/1) |
Alba |
Maryland Industrial Partnerships |
ND |
Funding support |
Funds will go toward completion of work on zonulin receptor cloning and characterization (2/21) |
Alba |
National Institute of Diabetes, Digestive and Kidney Diseases |
ND |
SBIR grant |
The grant will support development of Alba's lead molecule, AT-1001, for treating Type I diabetes (2/21) |
Alnylam |
U.S. Department of Defense |
ND |
Funding support |
The funds will support development of RNAi therapeutics for pandemic influenza (12/14) |
Arteriocyte Inc.* |
National Institutes of Health |
$1.4 |
STTR grant |
Funds will support a Phase I trial evaluating the safety of adult- derived hemangioblasts to treat chronic ischemia (1/19) |
Atom Sciences |
National Institutes of Health |
$0.6 |
Grant |
Funds will support development of a technology for rapid identification of disease pathogens in case of a biowarfare attack or a major outbreak(2/10) |
AVI BioPharma |
Department of Defense |
$11 |
Defense appropriation |
FY2006 appropriation bill includes $11M to fund ongoing programs studying Neugene technology for Ebola, Marburg and dengue viruses, and anthrax and ricin countermeasures (1/4) |
BiondVax Pharmaceuticals* (Israel) |
Israeli government |
$1.1 |
Funding support |
Funds will support development of its five-year, nasally administered, universal influenza vaccine (12/22) |
Biopure Corp. |
U.S. Navy |
$4 |
Defense |
FY2006 appropriations bill includes $4M in funding for the Navy to continue studying the use of Hemopure in trauma applications (1/3) |
Biota Holdings |
National Health and Medical Research Council (Australia) |
A$0.09 ($0.065) |
Grant |
Funds will support studies on a long-acting neuraminidase inhibitor against several avian flu strains (2/20) |
Bioxel Pharma |
Natural Sciences and Engineering Research Council of Canada |
C$0.273 ($0.234) |
Funding support |
The funding is to support formuation development of anticancer drugs; it will take the form of a grant, with installments paid upon completion of development milestones (12/16) |
Blue Heron |
National Institute of General Medical Science and the National Human Genome Research Institute |
$0.77 |
Phase II SBIR grant |
The grant will fund research to develop methods for assembling very large recombinant DNA molecules (3/13) |
Cepheid Inc. |
Canadian government |
C$0.78 ($0.69) |
Grant |
Cepheid and the Public Health Agency of Canada's National Microbiology Laboratory will use the funds to develop assays for Ebola, Marburg and Lassa fever viruses (2/14) |
Chaperone |
U.S. Army |
$1 |
Defense appropriation |
Chaperone, Lackawanna College and the University of Scranton will use the funds to develop methods for destroying drug-resistant bacteria (1/25) |
Chiron Corp. |
UK government |
ND |
Contract |
Contract calls for Chiron to supply the UK government pre-pandemic influenza vaccine for a stockpile based on the H5N1 avian influenza virus strain (2/24) |
CombiMatrix |
Department of Defense |
$2.1 |
Contract |
Conrtact focuses on integrating CombiMatrix's microarray technology with microelectronics and microfluidics to develop a system for detecting biothreats (2/13) |
CombiMatrix |
Department of Defense |
$2.4 |
Defense appropriation |
Funds will support further development of microarray technologies for detecting biological and chemical threat agents (1/17) |
Compugen Ltd. |
European Commission |
€3.1 ($3.7) |
Funding support |
Compugen is leading a consortium to develop a platform to simulate the cancer-related MAP kinase pathway; the consortium also includes Aureus Pharma and several institutions (3/7) |
Copernicus |
Cystic Fibrosis Foundation Therapeutics Inc. |
$1.5 |
Funding support |
The $1.5M in 2006 funding will support development of a gene therapy for CF; another $4.6M could be paid in 2007 if progress continues (2/14) |
GenVec Inc. |
National Institute of Allergy and Infectious Diseases |
$0.3 |
Subcontract funding |
Funds will support preliminary vector development in preparation for the manufacture of clinical-grade adenovector-based influenza vaccines (2/9) |
Iceland Genomics |
European Union |
ND |
Sixth Framework Program award |
A consortium including IGC, Bioinformatics ApS, University of Oxford and Radboud University will study the inherited risk of breast and prostate cancers (12/19) |
Illumina Inc. |
National Cancer Institute |
ND |
Subcontract award |
Illumina will perform whole- genome SNP scans on more than 2,500 prostate case and control samples, in support of the NCI's Cancer Genetic Markers of Susceptibility program(2/14) |
Invitrogen |
Department of Defense |
$0.97 |
Contract award |
Invitrogen Federal Systems will use the funding to produce and validate protein microarrays to biothreat agents (1/10) |
Iomai Corp. |
National Institute of Allergy and Infectious Diseases |
$1.4 |
Grant |
Funds will support development of an immunostimulant needle-free patch to extend availability of stocks of influenza vaccine in the case of a pandemic (3/9) |
Juvaris |
National Institute of Allergy and Infectious Diseases |
ND |
SBIR-Advanced Technology grant |
The 18-month grant will support testing of an HIV vaccine that uses Juvaris' JuvaVax vaccine platform (3/7) |
Juvaris |
National Institute of Allergy and Infectious Diseases |
ND |
STTR grant |
Juvaris and Stanford University will work on a next-generation influenza A vaccine, with an emphasis on avian influenza (1/9) |
Lentigen Corp. |
Maryland's Department of Business and Economic Development |
ND |
Challenge Investment Program funding |
The funding will support development of the company's lenti-viral technology (12/13) |
MaxThera Inc. |
National Institute of Allergy and Infectious Diseases |
$0.6 |
Phase I SBIR grant |
Two-year grant will support effort to design and develop antibiotics for infections complicated by antibiotic resistance (2/1) |
Medarex Inc. |
Department of Defense |
$2.05 |
Defense appropriation |
The funding will support development of Valortim, a fully human antibody being developed to prevent and treat anthrax infection (1/10) |
MNLpharma Ltd.*, |
Department of Trade and Industry (UK) |
£1.5 ($2.6) |
Grant |
The three-year matching grant will support development of a room- temperature, stable, controlled-release vaccine technology (3/17) |
Nanotrope |
National Aeronautics and Space Administration |
$0.6 |
Phase II SBIR grant |
Funds will support development of nanoscale technology for new drug formulations and delivery protocols (2/3) |
Northfield |
Department of Defense |
$3.5 |
Defense appropriation |
FY2006 appropriations bill includes $3.5M for continued development of PolyHeme, the company's hemoglobin-based oxygen carrier (1/3) |
Novavax Inc. |
National Institute of Allergy and Infectious Diseases |
$1 |
Funding support |
The additional money will fund the third year of a 4.5-year research program focused on an HIV/AIDS virus-like particle vaccine (3/16) |
PolyMedix Inc.* |
National Institute of Allergy and Infectious Diseases |
$3 |
Phase II SBIR grant |
Funds will be used to identify a lead compound and backups for an intravenous antibiotic to treat hospital-acquired infections (3/21) |
Procyon |
National Research Council Canada |
$0.98 |
Industrial Research Assistance Program contribution |
The repayable contribution will support development of the pro-tease inhibitor PPL-100 for treating drug-resistant HIV (1/13) |
ProlX |
National Cancer Institute |
$5.6 |
National Cooperative Drug Discovery Group award |
ProlX and four research institutions got the five-year award to discover therapies that target cells while minimizing damage to normal, healthy cells (12/7) |
ProteoTech Inc.* |
Michael J. Fox Foundation for Parkinson's Research |
$3.1 |
Funding award |
ProteoTech and collaborators will get up to $3.1M for work on a PD therapy that can disrupt or inhibit clumping of the protein alpha-synuclein (2/13) |
QBI Life |
National Institutes of Health |
$0.75 |
Roadmap for Medical Research grant |
QBI will develop a high-throughput molecular screening platform for membrane protein targets with the universities of Wisconsin and Helsinki (1/19) |
RheoGene Inc.* |
Michael J. Fox Foundation for Parkinson's Research |
$4.2 |
Funding award |
RheoGene will use the funds to develop its RheoSwitch Therapeutic System for gene therapy in Parkinson's disease (1/5) |
Semafore |
Indiana's 21st Century Research and Technology Fund |
$2.27 |
Grant |
The funds will help the company advance its lead targeted PI3 kinase inhibitor, SF1126, into Phase l trials in solid tumors later in 2006 (3/17) |
Sinovac |
China Ministry of Science and Technology |
RMB7 ($0.87) |
Funding support |
The funds will support preclinical trials of Sinovac's Panflu pandemic flu vaccine (12/9) |
Solbec |
Australian Industry Department |
A$2.26 ($1.66) |
AusIndustry Commercial Ready grant |
The funds are expected to cover half the cost of the upcoming Phase II trial of the cancer drug Coramsine (12/20) |
Transgene SA |
Lyone Biopole Competitive Cluster (France) |
€1.3 ($1.6) |
Grant |
The funds will support development over three years of the vaccine candidate TG4040 for treating hepatitis C (1/25) |
Notes: | ||||
* Indicates a privately held company. | ||||
Currency conversions reflect values at the time of a deal's announcement. | ||||
SBIR = Small Business Innovation Research; STTR = Small Business Technology Transfer. | ||||
Unless otherwise indicated, symbols listed are on the Nasdaq market. | ||||
# Item occured before the time frame of this chart but was not included in previous chart. | ||||
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; CDNX = Canadian Venture Exchange; TSE = Toronto Stock Exchange. | ||||
